A Prospective, Multicentre, Open Label, Non-Controlled, Observational, 26-Week Study in Patients Using NovoMix 30 (Biphasic Insulin Aspart 30) or Levemir (Insulin Detemir) for Treatment of Type 2 Diabetes Mellitus in Macedonia
Phase of Trial: Phase IV
Latest Information Update: 14 Oct 2014
At a glance
- Drugs Insulin aspart/insulin protamine aspart; Insulin detemir
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 14 Aug 2014 Actual patient number was changed from 1462 to 3421, according to the ClinicalTrials.gov record.
- 09 Jun 2011 Actual end date changed from Sep 2010 to Oct 2010 as reported by ClinicalTrials.gov.